bsm-54186R [Primary Antibody]
HDAC9 Recombinant Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: HDAC9

Clonality: Recombinant

Isotype: IgG

Entrez Gene: 9734

Swiss Prot: Q9UKV0

Source: Recombinant protein within human HDAC9 aa 1-150

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

In the intact cell, DNA closely associates with histones and other nuclear proteins to form chromatin. The remodeling of chromatin is a critical component of transcriptional regulation and the acetylation of nucleosomal histones is a major source of this remodeling. Acetylation of lysine residues in the amino terminal tail domain of histone results in an allosteric change in the nucleosomal conformation and an increased accessibility to transcription factors by DNA. Several mammalian proteins function as nuclear histone acetylases, including GCN5, PCAF (p300/CBP-associated factor), p300/CBP, HAT1 and the TFIID subunit TAF II p250. Conversely, the deacetylation of histones is associated with transcriptional silencing. The histone deacetylases (HDAC) include HDAC1-9. HDAC9 and HDAC9a are two alternatively spliced isoforms of HDAC9. HDAC9a is 132 amino acids shorter than HDAC9, but both isoforms contain the HDAC catalytic domain, remain capable of deacetylase activity and repress myoctye enhancer-binding factor 2-mediated transcription.

Size: 100ul

Concentration: 1ug/ul

Predicted Molecular Weight: 140


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Merve Ozdemir. et al. HDAC9/p300/F-actin immunoexpression and migration analysis for malignant melanoma stem cell. PATHOL RES PRACT. 2023 Oct;250:154829Read more>>
VALIDATION IMAGES

Lane 1: K562 Cells; Lane 2: HepG2 Cells; Lane 3: Raji Cells; Probed with HDAC9 (2C9) Monoclonal Antibody (bsm-54186R) at 1:1000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


Paraformaldehyde-fixed and paraffin-embedded Human Colon Cancer tissue incubated with HDAC9 (2C9) Monoclonal Antibody (bsm-54186R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with HDAC9 (2C9) Monoclonal Antibody (bsm-54186R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


4% Paraformaldehyde-fixed Raji (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (HDAC9) monoclonal Antibody, unconjugated (bsm-54186R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-40295G-FITC) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.


Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with HDAC9 (2C9) Monoclonal Antibody (bsm-54186R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.